Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer
Ligation of the inhibitory receptor NKG2A by its ligand HLA-E negatively regulates the activation of natural killer (NK) cells, as well as subsets of CD8+ T cells and innate T cell populations. NKG2A has recently become a novel immune checkpoint target for the treatment of cancer and direct antibody...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/12/1993 |
| _version_ | 1827636648417951744 |
|---|---|
| author | Jack G. Fisher Amber D. P. Doyle Lara V. Graham Salim I. Khakoo Matthew D. Blunt |
| author_facet | Jack G. Fisher Amber D. P. Doyle Lara V. Graham Salim I. Khakoo Matthew D. Blunt |
| author_sort | Jack G. Fisher |
| collection | DOAJ |
| description | Ligation of the inhibitory receptor NKG2A by its ligand HLA-E negatively regulates the activation of natural killer (NK) cells, as well as subsets of CD8+ T cells and innate T cell populations. NKG2A has recently become a novel immune checkpoint target for the treatment of cancer and direct antibody mediated blockade of NKG2A function is currently under assessment in two phase 3 clinical trials. In addition to direct targeting, the NKG2A:HLA-E axis can also be disrupted indirectly via multiple different targeted cancer agents that were not previously recognised to possess immunomodulatory properties. Increased understanding of immune cell modulation by targeted cancer therapies will allow for the design of rational and more efficacious drug combination strategies to improve cancer patient outcomes. In this review, we summarise and discuss the various strategies currently in development which either directly or indirectly disrupt the NKG2A:HLA-E interaction to enhance NK cell activation against cancer. |
| first_indexed | 2024-03-09T15:45:42Z |
| format | Article |
| id | doaj.art-56d633a0d3354294a0db745ec22ad2bf |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T15:45:42Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-56d633a0d3354294a0db745ec22ad2bf2023-11-24T18:30:47ZengMDPI AGVaccines2076-393X2022-11-011012199310.3390/vaccines10121993Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against CancerJack G. Fisher0Amber D. P. Doyle1Lara V. Graham2Salim I. Khakoo3Matthew D. Blunt4School of Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UKSchool of Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UKSchool of Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UKSchool of Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UKSchool of Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UKLigation of the inhibitory receptor NKG2A by its ligand HLA-E negatively regulates the activation of natural killer (NK) cells, as well as subsets of CD8+ T cells and innate T cell populations. NKG2A has recently become a novel immune checkpoint target for the treatment of cancer and direct antibody mediated blockade of NKG2A function is currently under assessment in two phase 3 clinical trials. In addition to direct targeting, the NKG2A:HLA-E axis can also be disrupted indirectly via multiple different targeted cancer agents that were not previously recognised to possess immunomodulatory properties. Increased understanding of immune cell modulation by targeted cancer therapies will allow for the design of rational and more efficacious drug combination strategies to improve cancer patient outcomes. In this review, we summarise and discuss the various strategies currently in development which either directly or indirectly disrupt the NKG2A:HLA-E interaction to enhance NK cell activation against cancer.https://www.mdpi.com/2076-393X/10/12/1993natural killer cellNK cellNKG2AHLA-Eimmunotherapycheckpoint blockade |
| spellingShingle | Jack G. Fisher Amber D. P. Doyle Lara V. Graham Salim I. Khakoo Matthew D. Blunt Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer Vaccines natural killer cell NK cell NKG2A HLA-E immunotherapy checkpoint blockade |
| title | Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer |
| title_full | Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer |
| title_fullStr | Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer |
| title_full_unstemmed | Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer |
| title_short | Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer |
| title_sort | disruption of the nkg2a hla e immune checkpoint axis to enhance nk cell activation against cancer |
| topic | natural killer cell NK cell NKG2A HLA-E immunotherapy checkpoint blockade |
| url | https://www.mdpi.com/2076-393X/10/12/1993 |
| work_keys_str_mv | AT jackgfisher disruptionofthenkg2ahlaeimmunecheckpointaxistoenhancenkcellactivationagainstcancer AT amberdpdoyle disruptionofthenkg2ahlaeimmunecheckpointaxistoenhancenkcellactivationagainstcancer AT laravgraham disruptionofthenkg2ahlaeimmunecheckpointaxistoenhancenkcellactivationagainstcancer AT salimikhakoo disruptionofthenkg2ahlaeimmunecheckpointaxistoenhancenkcellactivationagainstcancer AT matthewdblunt disruptionofthenkg2ahlaeimmunecheckpointaxistoenhancenkcellactivationagainstcancer |